Litigation Details for ELI LILLY AND COMPANY v. GLENMARK GENERICS INC., USA (S.D. Ind. 2014)
✉ Email this page to a colleague
ELI LILLY AND COMPANY v. GLENMARK GENERICS INC., USA (S.D. Ind. 2014)
| Docket | ⤷ Sign Up | Date Filed | 2014-01-23 |
| Court | District Court, S.D. Indiana | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Tanya Walton Pratt |
| Jury Demand | None | Referred To | Denise K. Larue |
| Patents | 7,772,209 | ||
| Link to Docket | External link to docket | ||
Details for ELI LILLY AND COMPANY v. GLENMARK GENERICS INC., USA (S.D. Ind. 2014)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2014-01-23 | 1 | prior to the expiration of U.S. Patent No. 7,772,209 (“the ’209 patent”). ALIMTA® is a chemotherapy agent… (Infringement of U.S. Patent No. 7,772,209) 13. Lilly incorporates… 1. This is an action for patent infringement under the patent laws of the United States, Title… assignee of the ’209 patent. As set forth in greater detail in the ’209 patent, one or more claims of…with respect to the ’209 patent, asserting that the claims of the ’209 patent are invalid, unenforceable | External link to document | |
| 2017-08-11 | 44 | August 10, 2010, U.S. Patent No. 7,772,209 (“Patent ’209”) was issued to Lilly. Patent ’209 covers the method… Eli Lilly and Company’s United States Patent No. 7,772,209. Case No. 1:10-cv-1373-TWP-DKL, ECF 420…claims of [Patent ’209]; d. in the event that the asserted claims of [Patent ’209] patent are invalidated… to the Patent Trial and Appeal Board (“PTAB”) seeking inter partes review (“IPR”) of Patent ’209. Glenmark…the Court that Patent ’209 is invalid. Additionally, even if the PTAB ruled that Patent ’209 was invalid | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
